-
摘要: 目的探讨原发性肝癌患者血清β2-微球蛋白(β2-microglobulin,β2-MG)含量变化及临床应用价值。方法用免疫放射分析法(RIA)检测64例原发性肝癌患者、55例肝硬化、以及48例正常健康人血清β2-MG含量;动态检测原发性肝癌手术前后β2-MG含量变化。结果原发性肝癌组血清中β2-MG含量明显高于健康对照组(P<0.05)和肝硬化组(P<0.05);原发性肝癌术前血清β2-MG含量增高者,术后含量明显降低,有转移复发时,β2-MG含量再度升高。结论检测血清β2-MG含量变化在原发性肝癌辅助诊断以及疗效、复发判断方面具有重要临床意义。Abstract: Objective To study the clinical evaluation of serum β2-MG in hepatocarcinoma.Methods By using RIA, the levels of serum β2-MG of the health adults, patients with hepatocarcinoma, liver cirrhosis (LC) , operative patients before and after operation.Results Serum β2-MG levels of hepatocarcinoma are higher than that of the health adults, patients with LC, In health adults and patients with LC there is no significantly difference of β2-MG.The high Serum β2-MG levels in preoperative patients were reduced dramatically after operation (P<0.01) , however, the reduced Serum β2-MG levels raised again when matastasis or recurrence occurred.Serum β2-MG is a singly tumor marker.Conclusion The examination of serum β2-MG is helpful to the differential diagnose in hepatocarcinoma and LC;and has important significance in judgement of therapeutic effects and relapse for hepatocarcinoma
-
Key words:
- hepatocarcinoma /
- β2-microglobulin
-
[1]Cao MG.Melanoma inhibiting activity protein (MIA) , beta-2microglobulin and lactate dehydrogenase (LDH) in metastatic mela-noma[J].Anticancer Res, 2007, 27 (11) ∶595-599. [2]Fujiwara K, Higashi T, Nouso K, et al.Decreased expression ofB7 costimulatory mole-cules and major histocompatibility complexclass-I in human hepatocellular carcinoma[J].J GastroenterolHepatol.2004, 19 (10) ∶1121-1127. [3]Obermann S, Petrykowska S, Manns MP, et al.Peptide-beta2-microglobulin-major histocompatibility complexexpressing cells arepotent antigen-presenting cells that can generate specific Tcells[J].Immunology, 2007, 122 (1) ∶90-97. [4]Prasanna SJ, Nandi D.The MHC-encoded class I molecule, H-2Kk, demonstrates distinct requirements of assembly factors for cellsurface expression∶roles of TAP, Tapasin and beta2-microglobu-lin[J].Mol Immunol, 2004, 41 (10) ∶1029-1045. [5]Ward DG, Cheng Y, N'Kontchou G, et al.Preclinical and post-treatment changes in the HCC-associated serum proteome[J].Br J Cancer, 2006, 95 (10) ∶1379-1380. [6]王凯, 袁孟彪, 王东盛, 等.β2微球蛋白对原发性肝癌鉴别诊断的价值[J].临床肝胆病杂志, 2002, 18 (5) ∶286-287.
本文二维码
计量
- 文章访问数: 2104
- HTML全文浏览量: 14
- PDF下载量: 837
- 被引次数: 0